Halia Therapeutics has completed the enrolment in its Phase IIa trial of HT-6184 (Ofirnoflast) in those with lower-risk myelodysplastic syndrome (MDS). The two-stage trial is designed to test the ...

A post-hoc analysis of the phase 3b JUMP trial assessed outcomes in patients with myelofibrosis and baseline anemia who were treated with ruxolitinib alongside anemia-supportive therapies, according ...

There are more than 700,000 prevalent cases of end-stage kidney disease in the United States, which is increasing by approximately 20,000 cases per year.1 Peritoneal dialysis is a home renal ...

The FDA noted that ESA therapy is intended to reduce transfusions and that the decision to use ESAs must be balanced by their risks. They also noted that patients should be clearly informed of the ...

A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

A total of 1751 patients with ESA-untreated NDD-CKD and 1725 with ESA-treated NDD-CKD underwent randomization in the two trials. In the pooled analysis, in which 1739 patients received vadadustat ...

Resistance to ESA therapy can occur in patients with malnutrition, folate or vitamin B 12 deficiency, secondary hyperparathyroidism, hemolysis, hemoglobinopathies, or primary bone marrow disorders ...

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic ...

Marie Chacon - Marie Chacon - ESA Letters, Marriage & Family Therapist, Los Angeles, CA, 90045, (661) 689-7912, My approach to therapy is to provide a supportive environment for change through ...

Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee Company Recommends Hemoglobin Target of 10-12 g/dL as Risk Management Approach THOUSAND ...